InMode (INMD) Revenue & Revenue Breakdown
InMode Revenue Highlights
Latest Revenue (Y)
$492.05M
Latest Revenue (Q)
$80.28M
InMode Revenue by Period
InMode Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $492.05M | 8.32% |
| 2022-12-31 | $454.27M | 27.05% |
| 2021-12-31 | $357.56M | 73.49% |
| 2020-12-31 | $206.11M | 31.81% |
| 2019-12-31 | $156.36M | 56.11% |
| 2018-12-31 | $100.16M | 87.37% |
| 2017-12-31 | $53.46M | - |
InMode generated $492.05M in revenue during NA 2023, up 8.32% compared to the previous quarter, and up 491.25% compared to the same period a year ago.
InMode Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $80.28M | -36.68% |
| 2023-12-31 | $126.78M | 2.98% |
| 2023-09-30 | $123.11M | -9.53% |
| 2023-06-30 | $136.08M | 28.29% |
| 2023-03-31 | $106.07M | -20.59% |
| 2022-12-31 | $133.57M | 10.18% |
| 2022-09-30 | $121.23M | 6.77% |
| 2022-06-30 | $113.55M | 32.15% |
| 2022-03-31 | $85.92M | -22.27% |
| 2021-12-31 | $110.54M | 17.38% |
| 2021-09-30 | $94.18M | 7.85% |
| 2021-06-30 | $87.33M | 33.27% |
| 2021-03-31 | $65.52M | -12.85% |
| 2020-12-31 | $75.19M | 25.91% |
| 2020-09-30 | $59.71M | 94.10% |
| 2020-06-30 | $30.77M | -23.93% |
| 2020-03-31 | $40.44M | -13.96% |
| 2019-12-31 | $47.00M | 17.48% |
| 2019-09-30 | $40.01M | 3.13% |
| 2019-06-30 | $38.80M | 26.99% |
| 2019-03-31 | $30.55M | 6.15% |
| 2018-12-31 | $28.78M | 13.24% |
| 2018-09-30 | $25.42M | 1.47% |
| 2018-06-30 | $25.05M | 19.79% |
| 2018-03-31 | $20.91M | - |
InMode generated $80.28M in revenue during Q1 2024, up -36.68% compared to the previous quarter, and up 60.11% compared to the same period a year ago.
InMode Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ABT | Abbott Laboratories | $40.11B | $10.63B |
| MDT | Medtronic | $32.36B | $7.92B |
| SYK | Stryker | $20.50B | $5.49B |
| EW | Edwards Lifesciences | $6.00B | $1.39B |
| ALGN | Align | $3.86B | $1.03B |
| DXCM | DexCom | $3.62B | $994.20M |
| ZBH | Zimmer Biomet | $1.94B | $143.40M |
| PODD | Insulet | $1.70B | $488.50M |
| TNDM | Tandem Diabetes Care | $747.72M | $331.03M |
| SWAV | ShockWave Medical | $730.23M | $218.81M |
| INSP | Inspire Medical Systems | $624.80M | $195.88M |
| NARI | Inari Medical | $493.63M | $153.39M |
| INMD | InMode | $492.05M | $80.28M |
| TMDX | TransMedics Group | $241.62M | $-12.24M |
INMD Revenue FAQ
What is InMode’s yearly revenue?
InMode's yearly revenue for 2023 was $492.05M, representing an increase of 8.32% compared to 2022. The company's yearly revenue for 2022 was $454.27M, representing an increase of 27.05% compared to 2021. INMD's yearly revenue for 2021 was $357.56M, representing an increase of 73.49% compared to 2020.
What is InMode’s quarterly revenue?
InMode's quarterly revenue for Q1 2024 was $80.28M, a -36.68% decrease from the previous quarter (Q4 2023), and a -24.31% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $126.78M, a 2.98% increase from the previous quarter (Q3 2023), and a -5.08% decrease year-over-year (Q4 2022). INMD's quarterly revenue for Q3 2023 was $123.11M, a -9.53% decrease from the previous quarter (Q2 2023), and a 1.55% increase year-over-year (Q3 2022).
What is InMode’s revenue growth rate?
InMode's revenue growth rate for the last 3 years (2021-2023) was 37.61%, and for the last 5 years (2019-2023) was 214.69%.